Illness behaviors and metabolic disturbances are common in pancreatic cancer patients, and may lead to wasting or cachexia. This devastating state of malnutrition is brought about by a synergistic combination of a decrease in appetite and an increase in metabolism of fat and lean body mass. The severity of cachexia in many illnesses is the primary determining factor in both quality of life, and in eventual mortality. Other illness- induced morbidities including lethargy also compromise the ability of patients to recover from life-saving or extending interventions, and diminish the motivational drive to aggressively battle the condition. Although cachexia in cancer patients was described more than two thousand years ago, the central mechanisms underlying this disorder are poorly understood. Furthermore, there is currently no effective pharmaceutical treatment. Our laboratory is dedicated to unraveling the basic neuroscience of cachexia. In this proposal, we will focus on understanding the scope and mechanism by which signals of pancreatic cancer development are received, amplified, and maintained by the hypothalamus. The significance of this proposal resides in its unique combination of our historical focus on neuroendocrinology and behavior, with new collaborations and efforts directed at understanding the role of extracellular vesicles in neuroinflammation. The long-term goal of our research is to gain mechanistic understanding of the acute illness response and how it is transitioned into chronic inflammation-associated cachexia in order to develop more effective therapeutic interventions.

Public Health Relevance

Involuntary weight loss, anorexia, fatigue, and loss of muscle are common in patients with pancreatic cancer. New research demonstrates that these problems limit quality of life for many patients, and also are a significant contributor to risk of death. Our studies are designed to investigate the ways in which pancreatic cancer leads to these disabling changes in behavior and metabolism to better understand how this might be treated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA217989-01A1
Application #
9518323
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Spalholz, Barbara A
Project Start
2018-05-10
Project End
2023-04-30
Budget Start
2018-05-10
Budget End
2019-04-30
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239